转移性前列腺癌患者采用PSMA PET/CT的RECIP 1.0疗效评估的预后价值:系统综述与Meta分析
该系统综述与Meta分析纳入8项研究共516例转移性前列腺癌患者,评估RECIP 1.0标准在PSMA PET/CT疗效评估中的预后价值。RECIP 1.0可显著区分疾病进展与非进展者的死亡风险(HR 3.48,95%CI 2.64-4.59),3项研究174例的汇总c-index为0.68(95%CI 0.65-0.71)。与PPP比较的3项研究224例显示非显著趋势 favoring RECIP 1.0。
要点
- RECIP 1.0可显著区分进展与非进展者的死亡风险(HR 3.48,95%CI 2.64-4.59)。
- 3项研究174例汇总c-index为0.68(95%CI 0.65-0.71)。
- 与PPP头对头比较的3项研究224例显示非显著趋势 favoring RECIP 1.0。
核心结论
- RECIP 1.0对评估转移性前列腺癌治疗结局具有稳健的预后价值。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、EMBASE和Web of Science截至2024年3月,纳入8项研究共516例接受PSMA PET/CT疗效评估的转移性前列腺癌患者,其中6项进行定量分析。
诊断标准与关键数值
- RECIP 1.0区分疾病进展与非进展的死亡风险HR为3.48(95%CI 2.64-4.59);3项研究174例的汇总c-index为0.68(95%CI 0.65-0.71)。
局限性
- 与PPP比较的3项研究224例仅显示非显著趋势 favoring RECIP 1.0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0). This system showed promising results in single-center studies. We aim to evaluate the prognostic performance of RECIP 1.0 in assessing treatment outcomes in metastatic prostate cancer patients with a systematic review and meta-analysis.
MATERIALS AND METHODS: Searches were conducted across PubMed/MEDLINE, EMBASE, and Web of Science databases through March 2024. Only studies involving patients with metastatic prostate cancer who underwent PSMA PET/CT to assess therapeutic response and who were evaluated using the RECIP 1.0 criteria were included. Pooled hazard ratios for mortality and concordance indices (c-index) of RECIP were assessed. A secondary analysis compared RECIP 1.0 to PSMA PET Progression Criteria (PPP) in head-to-head studies.
RESULTS: From an initial 553 reports, eight met the eligibility criteria after full-text review (n=516 patients) and six underwent quantitative analysis. RECIP 1.0 significantly differentiated between disease progression and non-progression in terms of mortality risk (HR: 3.48; 95% CI: 2.64-4.59). A sub-analysis of three studies with 174 patients demonstrated a pooled c-index of 0.68 (95% CI: 0.65-0.71). Comparison involving 224 patients from three studies indicated a non-significant trend favoring RECIP 1.0 over PPP.
CONCLUSION: RECIP 1.0 offers robust prognostic value for assessing metastatic prostate cancer treatment outcomes.
引用
- Mourato FA, Schmitt LG, Mariussi M, et al. Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis. Acad Radiol. 2025. PMID: 39755494. doi:10.1016/j.acra.2024.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。